DAY 1 PSFP ANNUAL CONVENTION (SEPT. 21, 2021)

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

EVALUATION FORM AND POST TEST

Email Address: *

Please write your name as you want it to appear on your certificate *

PMA Number *

Topic is relevant to my practice *

Strongly disagree

Strongly agree

Lectures and discussions contributed to my knowledge *

Strongly disagree

Strongly agree

The content presented in this convention was evidence-based, and free of commercial-bias *

Strongly disagree

Strongly agree

The technical aspects of the webinar was of good quality *

Strongly disagree

Strongly agree

OVERALL IMPRESSION OF THE CONVENTION *

Poor

Well

KINDLY RATE THE SPEAKER (DR. VIRGILIO M. NOVERO JR.)

Poor

Well

Clear selection

KINDLY RATE THE SPEAKER (DR. MARIE BELLE D. FRANCIA)

Poor

Well

Clear selection

KINDLY RATE THE SPEAKER (DR. ANGELA GAERLAN-TAGLE)

Poor

Well

Clear selection

KINDLY RATE THE SPEAKER (PROF. JERICHO THADDEUS P. LUNA)

Poor

Well

Clear selection

KINDLY RATE THE SPEAKER (DR. DORIS R. BENAVIDES)

Poor

Well

Clear selection

KINDLY RATE THE SPEAKER (DR. DANILO JOSE C. MILLA)

Poor

Well

Clear selection

KINDLY RATE THE SPEAKER (PROF. CLAUS YDING ANDERSEN)

Poor

Well

Clear selection

KINDLY RATE THE SPEAKER (DR. YASMIN C. GOSIENGFIAO)

Poor

Well

Clear selection

KINDLY RATE THE SPEAKER (DR. GLADYS G. TANANGONAN)

Poor

Well

Clear selection

KINDLY RATE THE SPEAKER (PROF. EILEEN M. MANALO)

Poor

Well

Clear selection

Based on what you learned from this convention, what will you do differently in your practice? *

Implement new information in the care of my patients

Create/revise protocols, policies, or procedures

Research additional information

I am already applying these concepts prior to this webinar

Required

Other comments & suggestions

POST TEST

Choose the best answer.

Fertility Preservation: Why bother?

1. How many percent of new cancer cases are expected to be potentially requiring fertility preservation? *

2. Most common cancer in postpubertal females requiring fertility preservation? *

Cervical Cancer

Ovarian Cancer

Breast Cancer

Thyroid Cancer

3. Most prevalent barrier among clinicians to implement fertility preservation based on a national survey? *

Awareness in Fertility Preservation

Availability of Fertility Preservation strategies

Patients approval

No time

4. Fertility preservation method with the highest chance for future pregnancy? *

Embryo cryopreservation

Oocyte cryopreservation

Ovarian Tissue cryopreservation

In vitro maturation

5. Most gonadotoxic cancer therapy to gametes? *

Alkylating agent group

Platinum based group

Targeted therapy group

Radiotherapy

Chemotherapy and Gonadotoxicity

1. A 30 year old male has been diagnosed with Hodgkin's Lymphoma Stage II. He is advised chemotherapy with ABVD. He belongs to a special population called Adolescents and Young Adults with Cancer as they have unique psychosocial and medical concerns. What is the age criteria for the above population as defined by NCCN 2021? *

10-14

15-39

40-49

50-55

2. Which class of chemotherapeutic agents are established to be at high risk for affecting fertility outcomes among cancer survivors? *

Platinum compounds (Cisplatin, Carboplatin)

Anthracyclines (Doxorubicin, Bleomycin)

Alkylating agents (Cyclophosphamide, Melphalan)

Targeted therapy (Bevacizumab, Erlotinib)

3. Which among the following mechanisms proposed causes chemotherapy induced gonadotoxicity? *

Chemotherapeutic agents causes double stranded DNA breaks (ds DNA) among primordial follicles which if remain unprepared by the ATM pathway may go to apoptosis.

Chemotherapeutic agents causes hyper activation of the PIK3CA pathway and hyperstimulation of primordial follicles causing negative feedback and decreasing AMH.

Chemotherapeutic agents damages the Sertoli cells in the gonads.

All of the above.

4. Population studies have shown that female cancer survivors have a 40% chance of becoming pregnant compare to general population. Is the statement True or False? *

True

False

5. Several professional organizations (ESMO, ASCO, NCCN) have established fertility preservation guidelines. Which among the following statements are included in their guidelines? *

Fertility counseling is standard for care to all cancer patients prior to undergoing cancer treatment. Ideally, we must refer to a fertility preservation specialist if possible.

Sperm cryopreservation (2-3x) is ideal for males desiring fertility preservation.

Egg preservation, embryo preservation, ovarian tissue preservation are options for women desiring fertility preservation prior to start of cancer treatment.

All of the above.

Radiotherapy and Gonadotoxicity

1. The following are true regarding male spermatogenesis except: *

There's fixed pool of stem cells present at birth.

There can be a latent and recovery phase.

Induction of sterility does not affect hormone balance, libido or physical capability.

It is a self-renewal system wherein sperm cells are continuously being produced throughout life.

2. The following are side effects of hypothalamic-pituitary axis disruption except: *

Gonadrotopin deficiency

Precocious puberty

Direct or indirect ovarian and testicular failure

None of the above

3. What is the radiation dose known to produce permanent sterility in males? *

0.15Gy

0.5Gy

3Gy

6Gy

4. What is the radiation dose known to produce permanent sterility in females? *

10Gy

12Gy

14Gy

16Gy

5. What is the radiation dose known to produce permanent sterility in premenopausal females? *

2Gy

4Gy

6Gy

8Gy

Experimental Strategies in Fertility Preservation

1. In vitro activation involves: *

A single laparoscopic procedure

AKT stimulation

PTEN stimulation

Soaking in ovarian stimulation medium for one day

2. Drug-Free IVA *

Involves two (2) laparoscopic procedures

No live births have been reported

Has been performed successfully in Japan, China, Spain and italy

A, B, C are correct

3. Experimental strategies to harmed the fertility potential in patients with established ovarian insufficiency or failure included except: *

In vitro activation

Co-treatment with Fertoprotective agents

Stem cell transplantation

Platelet-rich plasma infusion

4. Fertoprotective Agents: *

Inhibit ovarian reserve depletion by preventing primordial follicle apoptosis

Inhibit the activation of the P13K/PTEN/AKT signaling pathway

Are experimental

All are correct

5. The following are inhibitory to ovarian follicular activation: *

Insulin

BMP 4/7

Leukemia inhibiting factor

Hippo signaling pathway

Submit

Clear form

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

Forms